Pancreatic cancer, NRG1-positive

Section editor
	Eric I. Marks, MD Boston University Boston, MA, USA

Note: this page has regimens which are specific to pancreatic cancer that is NRG1-positive. Please see the main pancreatic cancer page for other chemotherapy regimens.

Last updated on 2024-07-23: 3 regimens on this page 3 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

• NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Pancreatic Adenocarcinoma.

Advanced or metastatic disease, subsequent lines of therapy

Zenocutuzumab monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Awaiting publication (eNRGy)	Not reported	Phase 1/2 (RT)

Biomarker eligibility criteria

• NRG1 fusion positive

Targeted therapy

• Zenocutuzumab (Bizengri) 750 mg IV once on day 1

14-day cycles

References

1. eNRGy: NCT02912949